Evidence map›Paper›PMID 42304319›Full record

Observational studyBMC cancer2026

Trajectory and predictors of cancer- and treatment-related fatigue (CRF) in adolescent and young adult cancer patients: a prospective, longitudinal study.

Alexandre Chan, Daniella Chan, Parisa Agrawal, Lucas Lee Beppu, Khai Kober, Ding Quan Ng, Michael Sayer, Julia Trudeau

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03476070 (Adolescent and Young Adult Cancer Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03476070 unknown statusnot on this map

Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)

TypeobservationalSponsorNational University of SingaporeRan2018 to 2022Enrolled236ConditionsBreast Cancer, Lymphoma, Germ Cell Tumor, Cognitive Impairment
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandre ChanDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.
Daniella ChanDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Parisa AgrawalDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Lucas Lee BeppuDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Khai KoberDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Ding Quan NgDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Michael SayerDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
Julia TrudeauDepartment of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.

Funding

Neurotrophic strategy to mitigate chemotherapy-related brain injuryR01CA276212 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Munjal M Acharya, Alexandre Chan · 2023 to 2026
$1.9M
National Institutes of Health (NIH) award R01CA276212National Medical Research Council Singapore CIRG1471NCI NIH HHS R01 CA276212
6 · The paper itself

Abstract

backgroundAlthough cancer- and treatment-related fatigue (CRF) is well recognized as a clinically important and distressing symptom among adolescent and young adult cancer (AYAC) patients, the understanding of the underlying mechanisms behind CRF in AYAC remains limited. We evaluated the trajectory and associated predictors of CRF among AYAC patients (Clinicaltrials.gov: NCT03476070, registered 03/23/2018).

methodsNewly diagnosed AYAC (15-39 years old) and non-cancer controls (NC) recruited from National Cancer Centre Singapore completed clinical assessments and provided blood draws for inflammatory cytokine measurements every 3 months up to 12 months. Mixed-effects models were used to evaluate significant factors associated with fatigue (MFSI-SF Total score), with AYAC stratified by chemotherapy status (active chemotherapy vs. >30 days post-chemotherapy).

resultsFifty AYAC and 105 NC participants were included, with nearly 1 in 3 AYAC participants reported clinically important CRF at some point. Measurements collected during active chemotherapy had a higher rate of clinically important CRF symptoms relative to samples collected post-chemotherapy and from non-cancer controls. Regression analyses evaluating significant influencers of fatigue scores demonstrated that active chemotherapy, female sex, worsened psychological distress scores, and increased IL-10 levels were associated with worse self-reported fatigue symptoms (all p < 0.05).

conclusionGiven the observed prevalence of clinically important CRF amongst AYAC within our study, our results further demonstrate that these patients are vulnerable to fatigue challenges. Identifying factors associated with these debilitating symptoms enables clinicians to better recognize at-risk patients and proactively address symptom burden.

Indexed as

FatigueNeoplasmsAdolescentAdultAntineoplastic AgentsCytokinesFemaleHumansLongitudinal StudiesMaleProspective StudiesYoung AdultAntineoplastic AgentsCytokinesAdolescent and young adult cancer patientsCancerCancer-related fatigueCytokinesFatigue

Identifiers

PMID42304319
PMCPMC13501642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.